Vigil Neuroscience, Inc. - VIGL STOCK NEWS

Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology firm, announced that CEO Ivana Magovčević-Liebisch will present at the 41^st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 8:15 a.m. PT / 11:15 a.m. ET. The event will be accessible via live webcast on their website, with an archived replay available for 90 days post-presentation. Vigil focuses on therapies for neurodegenerative diseases, notably through their lead candidate VGL101, which is in a Phase 2 trial for a rare disease known as ALSP.

Vigil Neuroscience, a clinical-stage biotechnology firm, has appointed Dr. David Gray as Chief Scientific Officer, effective February 27, 2023. Dr. Gray brings nearly 20 years of experience in neurological drug development. He replaces Dr. Spyros Papapetropoulos, who will leave on January 4, 2023, to pursue a CEO opportunity but will remain on Vigil's Scientific Advisory Board. The leadership change is expected to enhance the advancement of Vigil’s pipeline, particularly the development of VGL101 for treating neurodegenerative diseases.

Vigil Neuroscience (Nasdaq: VIGL) has initiated its first-ever interventional trial for patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare neurological disease. The Phase 2 IGNITE trial has begun dosing its first patient with VGL101, a monoclonal antibody aimed at treating this condition. Interim results from prior trials indicate that VGL101 is safe and effective in reducing biomarkers associated with ALSP. This study seeks to establish proof of concept by evaluating VGL101's safety, tolerability, and effects on disease progression.

Vigil Neuroscience (Nasdaq: VIGL) will host a Key Opinion Leader (KOL) event on December 6, 2022, in New York City, focusing on adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). The event aims to discuss the disease background, epidemiology, and the Phase 2 trial design for VGL101, the company’s lead product candidate targeting TREM2. The event features expert speakers and will be accessible via a live webcast. Vigil Neuroscience is dedicated to developing treatments for neurodegenerative diseases by restoring microglial function.

Vigil Neuroscience reported promising interim data from its Phase 1 trial of VGL101 in healthy volunteers, demonstrating safety and potential efficacy for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). The company is set to commence a Phase 2 trial this quarter, supported by a Fast Track designation from the FDA. Additionally, Vigil completed a $75 million PIPE financing, enhancing its cash runway to early 2025. The company reported a net loss of $17.5 million for Q3 2022, up from $10.7 million year-over-year due to rising operational costs.

Vigil Neuroscience (Nasdaq: VIGL) announced upcoming presentations at three investor conferences. The events include a fireside chat at Guggenheim's 4th Annual Immunology and Neurology Day on November 14, 2022, at 1:35 p.m. ET, followed by a chat at the Stifel 2022 Healthcare Conference on November 15, 2022, at 8:35 a.m. ET, and finally, a presentation at the Jefferies London Healthcare Conference on November 16, 2022, at 2:05 p.m. GMT. Live webcasts can be accessed on their website, and archived replays will be available for 90 days.

Vigil focuses on microglia for treating neurodegenerative diseases.

Vigil Neuroscience (VIGL) reported interim topline results from its Phase 1 clinical trial of VGL101 in healthy volunteers, establishing a foundation for a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). VGL101 demonstrated favorable safety and tolerability, with a robust reduction in cerebrospinal fluid (CSF) sTREM2 levels, indicating effective target engagement. The company is set to initiate the Phase 2 trial with a 20 mg/kg dosage this quarter, representing a significant milestone for the ALSP community.

Vigil Neuroscience (Nasdaq: VIGL) has received FDA Fast Track designation for its lead product candidate, VGL101, aimed at treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). This designation highlights the unmet medical needs of approximately 10,000 ALSP patients in the U.S. VGL101 is a TREM2 agonist currently undergoing a Phase 1 trial in healthy volunteers. The company aims to report Phase 1 topline data and initiate a Phase 2 proof-of-concept trial for VGL101 this quarter.

Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology firm, will participate in a fireside chat at the 2022 Morgan Stanley Global Healthcare Conference on September 12, 2022, at 4:50 p.m. ET. The event aims to showcase their focus on harnessing microglia for treating neurodegenerative diseases. Investors can access the live webcast through the company’s website in the 'Investors' section, with an archived replay available for 90 days post-event.

Vigil Neuroscience specializes in developing therapies to restore microglial function, addressing both rare and common diseases.